News

The US based biotechnology company plans to make hemophilia business a publicly traded independent company, so that each of the company will focus on their respective areas of

As per the agreement, Ionis will receive up to $95m and will earn royalties on global sales of Kynamro starting in 2017. Ionis will also receive a 10%

The complainant is a 62-year-old American woman named Gloria Ristesund. She said that she had used J&J’s talc-based powder products, which include the Baby Powder and Shower to

Spero Oncology is a UK-based CRO specializing in providing clinical operations support for oncology clinical trials primarily throughout Europe, but also in Australia and New Zealand. With the

The dose of PRTX-100 for subjects in the next treatment group (6.0 micrograms/kg) will be twice that of the initial starting dosage (3.0 micrograms/kg). PRTX-100, Protalex’s lead drug

The new building will span more than 30,000 square feet and accommodate approximately 120 new and current employees whose focus will be on accelerating innovation in R&D, with

SER-109 is an oral, potential first-in-field microbiome therapeutic that has been granted Orphan Drug and Breakthrough Therapy designations by the U.S. Food and Drug Administration (FDA), and is

Shipments to customers have already commenced. BenzaClin® Pump Topical Gel (clindamycin phosphate 1% and benzoyl peroxide 5%) is indicated for the topical treatment of acne vulgaris. Combined generic

Cortivera-H has been approved for pharma care reimbursement program in the BC formulary, and is in the process to get listed in other provincial formularies. Cortivera-H, a made